Skip to main content

CASE REPORT article

Front. Immunol.
Sec. Inflammation
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1492547

Dupilumab Combined with Corticosteroid Therapy for Kimura Disease with Multiple Systemic Masses: A Case Report and Literature Review

Provisionally accepted
Yansi Lyu Yansi Lyu 1Ma Li Ma Li 1Lvxin Guan Lvxin Guan 2Ziping Wen Ziping Wen 1Jingkai Huang Jingkai Huang 1Minglan Shi Minglan Shi 1Suchun Hou Suchun Hou 1*
  • 1 Department Of Dermatology, Shenzhen University General Hospital, Shenzhen, China
  • 2 Department of Burn and Plastic Surgery, the First Affiliated Hospital of Shenzhen University, Shenzhen, China

The final, formatted version of the article will be published soon.

    To date, the pathogenesis of Kimura's disease remains unclear, there is no unified diagnostic criterion, the clinical phenotype shows considerable heterogeneity, and there is a lack of optimal treatment strategies. Due to its rarity, treatment strategies for KD are still under exploration. This paper reports a case of a 37-year-old Chinese female presenting with generalized erythematous papules and pruritic eruptions for 12 years, followed by the onset of limb swellings 3 years later, ultimately diagnosed as Kimura's disease. Considering the patient's multiple lymphadenopathies and limb swellings with concurrent atopic dermatitis, the treatment regimen included initial dupilumab dosage of 600 mg (300 mg administered in two injections), followed by subcutaneous injections of 300 mg every two weeks for four months. Concurrent oral corticosteroid therapy (methylprednisolone, initial dose 16 mg/kg/day, gradually tapered with tumor regression) was also administered. Following treatment, the patient did not experience severe adverse effects, and the multiple nodules markedly decreased in size.Additionally, serum IgE levels, eosinophil, and basophil counts showed significant reductions. These results demonstrate the significant efficacy of dupilumab combined with oral corticosteroids in treating Kimura's disease with concurrent atopic dermatitis.

    Keywords: Dupilumab, corticosteroid, combination therapy, Kimura disease, Multiple Systemic Masses

    Received: 07 Sep 2024; Accepted: 07 Oct 2024.

    Copyright: © 2024 Lyu, Li, Guan, Wen, Huang, Shi and Hou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Suchun Hou, Department Of Dermatology, Shenzhen University General Hospital, Shenzhen, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.